• Consensus Rating: Buy
  • Consensus Price Target: C$3.13
  • Forecasted Upside: 69.84%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$1.84
▼ -0.07 (-3.66%)

This chart shows the closing price for OGI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Organigram Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGI

Analyst Price Target is C$3.13
▲ +69.84% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Organigram in the last 3 months. The average price target is C$3.13, with a high forecast of C$3.25 and a low forecast of C$3.00. The average price target represents a 69.84% upside from the last price of C$1.84.

This chart shows the closing price for OGI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Organigram. This rating has held steady since January 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/11/2026ATB Cormark Capital MarketsDowngradeStrong-Buy ➝ Moderate BuyC$3.50 ➝ C$3.25
1/27/2026Canaccord Genuity GroupSet TargetBuyC$3.00
12/17/2024ATB Cormark Capital MarketsLower TargetC$5.25 ➝ C$3.50
12/9/2024Canaccord Genuity GroupLower TargetSpeculative BuyC$3.60 ➝ C$3.15
8/14/2024Canaccord Genuity GroupBoost TargetSpeculative BuyC$3.25 ➝ C$3.60
5/17/2024Jefferies Financial GroupLower TargetC$4.40 ➝ C$4.35
5/15/2024Canaccord Genuity GroupLower TargetSpeculative BuyC$3.75 ➝ C$3.25
4/3/2024ATB Cormark Capital MarketsSet TargetOutperformC$5.25
2/27/2024Jefferies Financial GroupLower TargetBuyC$4.95 ➝ C$4.40
2/14/2024Alliance Global PartnersBoost TargetNeutralC$2.00 ➝ C$2.70
12/20/2023ATB Cormark Capital MarketsBoost TargetOutperformC$5.50 ➝ C$6.50
12/20/2023Alliance Global PartnersLower TargetC$2.25 ➝ C$2.00
12/20/2023Canaccord Genuity GroupLower TargetC$4.00 ➝ C$3.75
7/18/2023Haywood SecuritiesLower TargetC$5.00 ➝ C$3.00
7/17/2023Stifel NicolausBoost TargetC$1.25 ➝ C$4.00
7/17/2023Alliance Global PartnersBoost TargetC$1.00 ➝ C$2.25
7/17/2023ATB Cormark Capital MarketsLower TargetC$9.00 ➝ C$6.50
7/17/2023Canaccord Genuity GroupLower TargetC$9.00 ➝ C$4.00
4/21/2023Jefferies Financial GroupLower TargetC$1.80 ➝ C$1.50
4/13/2023ATB Cormark Capital MarketsLower TargetC$2.50 ➝ C$2.25
4/13/2023Canaccord Genuity GroupLower TargetC$3.25 ➝ C$2.25
4/13/2023Haywood SecuritiesLower TargetC$1.60 ➝ C$1.25
4/13/2023Stifel NicolausLower TargetC$1.50 ➝ C$1.25
2/28/2023Jefferies Financial GroupLower TargetC$2.00 ➝ C$1.80
1/13/2023Alliance Global PartnersLower TargetC$1.50 ➝ C$1.30
1/13/2023Stifel NicolausUpgradeHold ➝ Buy
12/23/2022Jefferies Financial GroupLower TargetC$2.60 ➝ C$2.00
8/31/2022Eight CapitalLower TargetC$2.60 ➝ C$1.70
7/19/2022Jefferies Financial GroupLower TargetMarket PerformC$3.34 ➝ C$2.60
7/15/2022Haywood SecuritiesLower TargetHoldC$2.50 ➝ C$1.90
7/15/2022Stifel NicolausLower TargetC$2.25 ➝ C$1.50
4/14/2022Raymond James FinancialSet TargetOverweightC$3.00
4/13/2022Jefferies Financial GroupLower TargetC$3.44 ➝ C$3.34
4/13/2022ATB Cormark Capital MarketsUpgradeSector Perform ➝ OutperformC$3.00
4/12/2022ATB Cormark Capital MarketsUpgradeSector Perform ➝ Outperform
3/15/2022Raymond James FinancialLower TargetOutperformC$5.00 ➝ C$3.00
1/12/2022ATB Cormark Capital MarketsBoost TargetSector PerformC$2.65 ➝ C$3.00
1/12/2022Canaccord Genuity GroupUpgradeHold ➝ Speculative BuyC$3.00 ➝ C$3.25
1/10/2022Raymond James FinancialReiterated RatingOutperformC$5.00
1/7/2022Alliance Global PartnersLower TargetNeutral ➝ UnderperformC$4.00 ➝ C$2.25
12/22/2021Raymond James FinancialReiterated RatingOutperformC$5.00
11/30/2021Jefferies Financial GroupLower TargetMarket PerformC$3.83 ➝ C$3.49
11/25/2021Raymond James FinancialSet TargetOutperformC$5.00
11/24/2021Alliance Global PartnersLower TargetUnderperformC$3.75 ➝ C$3.00
11/24/2021ATB Cormark Capital MarketsLower TargetC$4.25 ➝ C$2.65
11/19/2021Raymond James FinancialSet TargetOutperformC$5.00
9/24/2021Canadian Imperial Bank of CommerceReiterated RatingNeutral
9/23/2021Canadian Imperial Bank of CommerceLower TargetNAC$4.00 ➝ C$3.50
9/15/2021Raymond James FinancialReiterated RatingOutperformC$5.00
9/3/2021Jefferies Financial GroupBoost TargetC$3.57 ➝ C$3.83
8/5/2021Raymond James FinancialReiterated RatingOutperformC$5.00
7/23/2021ATB Cormark Capital MarketsReiterated RatingSector Perform
7/14/2021Raymond James FinancialReiterated RatingOutperformC$5.00
7/14/2021ATB Cormark Capital MarketsBoost TargetNAC$3.75 ➝ C$4.25
7/14/2021Canadian Imperial Bank of CommerceBoost TargetC$3.75 ➝ C$4.00
7/9/2021Canadian Imperial Bank of CommerceReiterated RatingNeutralC$3.75
7/8/2021Raymond James FinancialReiterated RatingOutperformC$5.00
6/11/2021Canadian Imperial Bank of CommerceBoost TargetUnderperformC$3.25 ➝ C$3.75
5/11/2021Canadian Imperial Bank of CommerceUpgradeUnderperform ➝ Neutral
5/11/2021Royal Bank Of CanadaUpgradeNeutral
5/4/2021Raymond James FinancialReiterated RatingOutperformC$5.00
4/22/2021Jefferies Financial GroupBoost TargetC$3.48 ➝ C$3.57
4/15/2021Alliance Global PartnersLower TargetUnderpeformC$4.00 ➝ C$3.75
4/14/2021Haywood SecuritiesLower TargetUnderperformC$4.75 ➝ C$3.50
4/14/2021ATB Cormark Capital MarketsLower TargetUnderperformC$4.20 ➝ C$3.75
4/14/2021Alliance Global PartnersBoost TargetUnderperformC$3.75 ➝ C$4.00
4/14/2021Canadian Imperial Bank of CommerceDowngradeNeutral ➝ UnderperformC$5.00 ➝ C$3.25
4/13/2021Raymond James FinancialLower TargetOutperformC$6.00 ➝ C$5.00
4/7/2021Raymond James FinancialReiterated RatingOutperformC$6.00
4/6/2021Canadian Imperial Bank of CommerceReiterated RatingNeutralC$5.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/20/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2025
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/19/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/19/2026

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

  • No very positive mentions tracked during this time.
Organigram logo
Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.
Read More

Today's Range

Now: C$1.84
Low: C$1.82
High: C$1.89

50 Day Range

MA: C$2.05
Low: C$1.74
High: C$2.40

52 Week Range

Now: C$1.84
Low: C$1.22
High: C$3.09

Volume

138,007 shs

Average Volume

240,175 shs

Market Capitalization

C$248.66 million

P/E Ratio

11.95

Dividend Yield

N/A

Beta

1.8059

Frequently Asked Questions

What sell-side analysts currently cover shares of Organigram?

The following Wall Street analysts have issued reports on Organigram in the last year: ATB Cormark Capital Markets, and Canaccord Genuity Group Inc..
View the latest analyst ratings for OGI.

What is the current price target for Organigram?

0 Wall Street analysts have set twelve-month price targets for Organigram in the last year. Their average twelve-month price target is C$3.13, suggesting a possible upside of 63.6%. ATB Cormark Capital Markets has the highest price target set, predicting OGI will reach C$3.25 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of C$3.00 for Organigram in the next year.
View the latest price targets for OGI.

What is the current consensus analyst rating for Organigram?

Organigram currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OGI will outperform the market and that investors should add to their positions of Organigram.
View the latest ratings for OGI.

What other companies compete with Organigram?

How do I contact Organigram's investor relations team?

Organigram's physical mailing address is 333 Bay Street, Suite 1250, Toronto, ON M5H 2R2, Canada, . The company's listed phone number is 844-644-4726. The official website for Organigram is www.organigram.ca. Learn More about contacing Organigram investor relations.